Efficacy of a Single Intra-Articular HYMOVIS ONE Injection for Managing Symptomatic Hip Osteoarthritis: A 12-Month Follow-Up Retrospective Analysis of the ANTIAGE Register Data

Figures & data

Table 1 Characteristics of the Study Cohort at Baseline

Patients (n)	198
Men	114 (57.5%)
Women	84 (42.5%)
Age, years, mean (SD)	62 (± 14.2)
BMI, mean (SD)	26.3 (± 2.5)
Weight, kg, mean (SD)	73.7 (± 10.6)
Height, cm, mean (SD)	169.7 (± 7.2)
Lequesne index, mean (SD)	11.5 (± 2.5)
Pain VAS, mean (SD)	6.4 (± 2.2)
NSAID intake (days/months mean, (SD))	16.3 (± 4.6)
Age classes
<65 y.o.	95 (48.0%)
>65 y.o.	103 (52.0%)
Hip affected
Right	85 (42.9%)
Left	74 (37.4%)
Bilateral	39 (19.7%)
Kellgren–Lawrence radiological index
Grade I	18 (9.1%)
Grade II	79 (39.9%)
Grade III	101 (51.0%)

Figure 1 Decrease in pain over time, measured through a visual analogue scale (VAS). The decrease is statistically significant (p<0.05) from baseline to 6 months and 12 months.

Figure 2 Decrease in Lequesne index over time. The decrease is statistically significant (p<0.05) both from baseline to 6 and 12 months, and between 6 and 12 months.

Figure 3 Decrease in NSAID consumption over time, measured in days/months. The decrease is statistically significant (p<0.05) both from baseline to 6 and 12 months, and between 6 and 12 months.

Table 2 Pain VAS, Lequesne Index, and NSAID Consumption Variation Over Time

	Baseline	6 Months	%	12 Months	%
Pain VAS	6.4 ± 2.2	5.4 ± 2.0* (p=0.002)	−15.6	5.3 ± 1.9* (p=0.004)	−17.2
Lequesne index	11.5 ± 4.6	9.3 ± 3.7* (p=0.012)	−19.0	7.6 ± 2.4* (p=0.008)	−33.7
NSAIDs consumption (days/month)	16.3 ± 6.0	12.8 ± 3.2* (p=0.007)	−21.8	9.5 ± 2.1* (p=0.009)	−41.7

Notes: All values are given as the mean ± SD. *Significant difference compared to pre-treatment (p<0.05); % variations are calculated from baseline.